OptimizeRx (OPRX) Cash & Equivalents (2010 - 2026)

OptimizeRx has disclosed Cash & Equivalents across 17 years of filings, most recently posting $24.1 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 45.29% year-over-year to $24.1 million; the TTM figure through Jun 2026 stood at $24.1 million (up 45.29% YoY), while the FY2025 annual figure was $23.4 million, up 74.63% from the prior year.
• Cash & Equivalents came in at $24.1 million for Q2 2026 at OptimizeRx, up from $20.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $89.0 million in Q1 2022 to a low of $9.8 million in Q2 2023.
• Average Cash & Equivalents over 5 years is $25.9 million, with a median of $16.6 million recorded in 2025.
• Year-over-year, Cash & Equivalents tumbled 88.78% in 2023 and surged 74.63% in 2025.
• Over 5 years, Cash & Equivalents stood at $18.2 million in 2022, then retreated by 23.93% to $13.9 million in 2023, then slipped by 3.41% to $13.4 million in 2024, then surged by 74.63% to $23.4 million in 2025, then gained by 3.13% to $24.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $24.1 million in Q2 2026, $20.2 million in Q1 2026, and $23.4 million in Q4 2025.